Hydroxychloroquine: An old drug with new relevance

REFERENCES

1. ↵
   1. Sanofi-Aventis

   . Product monograph: Plaquenil. http://products.sanofi.ca/en/plaquenil.pdf. Accessed May 2, 2018.
2. ↵
   1. Centers for Disease Control and Prevention (CDC)

   . Malaria information and prophylaxis, by country. www.cdc.gov/malaria/travelers/country_table/a.html. Accessed May 2, 2018.
3. ↵
   1. Wallace DJ

   . The history of antimalarials. Lupus 1996; 5(suppl 1):S2–S3. pmid:8803902

   OpenUrlCrossRefPubMed
4. ↵
   1. Shee JC

   . Lupus erythematosus treated with chloroquine. Lancet 1953; 265(6778):201–202. pmid:13070595

   OpenUrlPubMed
5. ↵
   1. Kuznik A,
   2. Bencina M,
   3. Svajger U,
   4. Jeras M,
   5. Rozman B,
   6. Jerala R

   . Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186:4794–4804. doi:10.4049/jimmunol.1000702

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Willis R,
   2. Seif AM,
   3. McGwin G Jr.,
   4. et al

   . Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA, a multiethnic US cohort. Lupus 2012; 21(8):830–835. doi:10.1177/0961203312437270

   OpenUrlCrossRefPubMed
7. ↵
   1. Fox R

   . Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5(suppl 1):S4–S10. pmid:8803903

   OpenUrlCrossRefPubMed
8. ↵
   1. Ruiz-Irastorza G,
   2. Ramos-Casals M,
   3. Brito-Zeron P,
   4. Khamashta MA

   . Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69(1):20–28. doi:10.1136/ard.2008.101766

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Lam NC,
   2. Ghetu MV,
   3. Bieniek ML

   . Systemic lupus erythematosus: primary care approach to diagnosis and management. Am Fam Physician 2016; 94(4):284–294. pmid:27548593

   OpenUrlPubMed
10. ↵
    1. Jung H,
    2. Bobba R,
    3. Su J,
    4. et al

    . The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62(3):863–868. doi:10.1002/art.27289

    OpenUrlCrossRefPubMed
11. ↵
    1. Nuri E,
    2. Taraborelli M,
    3. Andreoli L,
    4. et al

    . Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017; 65(1):17–24. doi:10.1007/s12026-016-8812-z

    OpenUrlCrossRef
12. ↵
    1. Erkan D,
    2. Aguiar CL,
    3. Andrade D,
    4. et al

    . 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13(6):685–696. doi:10.1016/j.autrev.2014.01.053

    OpenUrlCrossRefPubMed
13. ↵
    1. Jalal H,
    2. O’Dell JR,
    3. Bridges SL Jr.,
    4. et al

    . Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68(12):1751–1757. doi:10.1002/acr.22895

    OpenUrlCrossRef
14. ↵
    1. Avina-Zubieta JA,
    2. Galindo-Rodriguez G,
    3. Newman S,
    4. Suarez-Almazor ME,
    5. Russell AS

    . Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998; 57(10):582–587. pmid:9893568

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Gottenberg JE,
    2. Ravaud P,
    3. Puechal X,
    4. et al

    . Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome. JAMA 2014; 312(3):249–258. doi:10.1001/jama.2014.7682

    OpenUrlCrossRefPubMed
16. ↵
    1. Petri M

    . Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5(suppl 1):S16–S22. pmid:8803905

    OpenUrlCrossRefPubMed
17. ↵
    1. Cairoli E,
    2. Rebella M,
    3. Danese N,
    4. Garra V,
    5. Borba EF

    . Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012; 21(11):1178–1182. doi:10.1177/0961203312450084

    OpenUrlCrossRefPubMed
18. ↵
    1. Charles-Schoeman C,
    2. Wang X,
    3. Lee YY,
    4. et al

    . Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheumatol 2016; 68(3):577–586. doi:10.1002/art.39502

    OpenUrlCrossRefPubMed
19. ↵
    1. Penn SK,
    2. Kao AH,
    3. Schott LL,
    4. et al

    . Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010; 37(6):1136–1142. doi:10.3899/jrheum.090994

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Wasko MC,
    2. Hubert HB,
    3. Lingala VB,
    4. et al

    . Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298(2):187–193. doi:10.1001/jama.298.2.187

    OpenUrlCrossRefPubMed
21. ↵
    1. Sun L,
    2. Liu M,
    3. Li R,
    4. et al

    . Hydroxychloroquine, a promising choice for coronary artery disease? Med Hypotheses 2016; 93:5–7. doi:10.1016/j.mehy.2016.04.045

    OpenUrlCrossRef
22. ↵
    1. Tett SE,
    2. Cutler DJ,
    3. Day RO,
    4. Brown KF

    . Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27(6):771–779. pmid:2757893

    OpenUrlCrossRefPubMed
23. ↵
    1. Furst DE

    . Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996; 5(suppl 1):S11–S15. pmid:8803904

    OpenUrlCrossRefPubMed
24. ↵
    1. Frances C,
    2. Cosnes A,
    3. Duhaut P,
    4. et al

    . Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus. Arch Dermatol 2012; 148(4):479–484. doi:10.1001/archdermatol.2011.2558

    OpenUrlCrossRefPubMed
25. ↵
    1. Chasset F,
    2. Arnaud L,
    3. Costedoat-Chalumeau N,
    4. Zahr N,
    5. Bessis D,
    6. Francès C

    . The effect of increasing the dose of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: an open-label prospective pilot study. J Am Acad Dermatol 2016; 74(4):693–699.e3. doi:10.1016/j.jaad.2015.09.064

    OpenUrlCrossRefPubMed
26. ↵
    1. Melles RB,
    2. Marmor MF

    . The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132(12):1453–1460. doi:10.1001/jamaophthalmol.2014.3459

    OpenUrlCrossRefPubMed
27. ↵
    1. Committee on Rheumatologic Care

    . American College of Rheumatology position statement. Screening for hydroxychloroquine retinopathy. www.rheumatology.org/Portals/0/Files/Screening-for-Hydroxychloroquine-Retinopathy-Position-Statement.pdf. Accessed April 2, 2018.
28. ↵
    1. Marmor MF,
    2. Kellner U,
    3. Lai TY,
    4. Melles RB,
    5. Mieler WF,
    6. American Academy of Ophthalmology

    . Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123(6):1386–1394. doi:10.1016/j.ophtha.2016.01.058

    OpenUrlCrossRefPubMed
29. ↵
    1. Mackenzie AH

    . Antimalarial drugs for rheumatoid arthritis. Am J Med 1983; 75(6A):48–58. pmid:6362406

    OpenUrlPubMed
30. ↵
    1. Mackenzie AH

    . Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75(1A):40–45. pmid:6869410

    OpenUrlPubMed
31. ↵
    1. Melles RB,
    2. Marmor MF

    . Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122(1):110–116. doi:10.1016/j.ophtha.2014.07.018

    OpenUrlCrossRef
32. ↵
    1. Uslu H,
    2. Gurler B,
    3. Yildirim A,
    4. et al

    . Effect of hydroxychloroquine on the retinal layers: a quantitative evaluation with spectral-domain optical coherence tomography. J Ophthalmol 2016; 2016:8643174. doi:10.1155/2016/8643174

    OpenUrlCrossRef
33. ↵
    1. Au A,
    2. Parikh V,
    3. Modi YS,
    4. Ehlers JP,
    5. Schachat AP,
    6. Singh RP

    . Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am J Ophthalmol 2015; 160(3):561–568.e2. doi:10.1016/j.ajo.2015.06.009

    OpenUrlCrossRef
34. ↵
    1. Jallouli M,
    2. Frances C,
    3. Plette JC,
    4. et al
    5. Plaquenil Lupus Systemic Study Group

    . Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus. JAMA Dermatol 2013; 149(8):935–940. doi:10.1001/jamadermatol.2013.709

    OpenUrlCrossRefPubMed
35. ↵
    1. Avina-Zubieta JA,
    2. Johnson ES,
    3. Suarez-Almazor ME,
    4. Russell AS

    . Incidence of myopathy in patients treated with antimalarials: a report of three cases and review of the literature. Br J Rheumatol 1995; 34(2):166–170. pmid:7704464

    OpenUrlCrossRefPubMed
36. ↵
    1. Yogasundaram H,
    2. Putko BN,
    3. Tien J,
    4. et al

    . Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 2014; 30:1706–1715. doi:10.1016/j.cjca.2014.08.016

    OpenUrlCrossRefPubMed
37. ↵
    1. Pearson KC,
    2. Morrell DS,
    3. Runge SR,
    4. Jolly P

    . Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis 2016; 97(3):212–216. pmid:27023083

    OpenUrlPubMed
38. ↵
    1. Youngster I,
    2. Arcavi L,
    3. Schechmaster R,
    4. et al

    . Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33(9):713–726. doi:10.2165/11536520-000000000-00000

    OpenUrlCrossRefPubMed
39. ↵
    1. Ostensen M,
    2. Khamashta M,
    3. Lockshin M,
    4. et al

    . Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8(3):209. doi:10.1186/ar1957

    OpenUrlCrossRefPubMed
40. ↵
    1. Leroux M,
    2. Desveaux C,
    3. Parcevaux M,
    4. et al

    . Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24(13):1384–1391. doi:10.1177/0961203315591027

    OpenUrlCrossRefPubMed
41. ↵
    1. Clowse MEB,
    2. Magder L,
    3. Witter F,
    4. Petri M

    . Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54(11):3640–3647. doi:10.1002/art.22159

    OpenUrlCrossRefPubMed
42. ↵
    1. Levy RA,
    2. Vilela VS,
    3. Cataldo MJ,
    4. et al

    . Hydroxychloroquine in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10(6):401–404. doi:10.1191/096120301678646137

    OpenUrlCrossRefPubMed
43. ↵
    1. James JA,
    2. Kim-Howard XR,
    3. Bruner BF,
    4. et al

    . Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16(6):401–409. doi:10.1177/0961203307078579

    OpenUrlCrossRefPubMed
44. ↵
    1. Akpovwa H

    . Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct 2016; 34(4):191–196. doi:10.1002/cbf.3182

    OpenUrlCrossRefPubMed
45. ↵
    1. Pascolo S

    . Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol 2016; 771:139–144. doi:10.1016/j.ejphar.2015.12.017

    OpenUrlCrossRefPubMed
46. ↵
    1. Furlong HC,
    2. Wessels JM,
    3. Guerra MT,
    4. Stämpfli MR,
    5. Foster WG

    . Hydroxychloroquine attenuates cigarette smoke induced autophagic signaling in the mouse ovary. Reprod Toxicol 2016; 61:105–113. doi:10.1016/j.reprotox.2016.03.044

    OpenUrlCrossRef
47. ↵
    1. Cairoli E,
    2. Danese N,
    3. Teliz M,
    4. et al

    . Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study. Lupus 2015; 24(11):1204–1209. doi:10.1177/0961203315580870

    OpenUrlCrossRefPubMed